Skip to main content
. 2023 Jul 25;10:1224506. doi: 10.3389/fmed.2023.1224506

Table 1.

Baseline demographics and characteristics of patients.

NASH (n = 38) HBV (n = 82) p value
Age 56.7 ± 8.8 49.2 ± 9.4 <0.001
Female 21 (55.3) 17 (20.7) <0.001
BMI (kg/m2) 24.7 ± 4.1 21.7 ± 2.6 0.032
Overweight/Obese 18 (47.4) 9 (11.0) <0.001
Ascites 0.319
Mild 15 (39.5) 33 (40.2)
Moderate/Excessive 4 (10.5) 17 (20.7)
Metabolic syndrome 19 (50.0) 6 (7.3) <0.001
Esophageal varices 34 (89.5) 77 (93.9) 0.392
Gastric varices 30 (78.9) 66 (80.5) 0.844
Hypertension 8 (21.0) 5 (6.1) 0.014
Diabetes 28 (73.7) 27 (32.9) <0.001
Hypertriglyceridemia 10 (26.3) 0 <0.001
Child–Pugh score 6.7 ± 1.5 7.2 ± 1.7 0.097
Child–Pugh class 0.124
Child class A 22 (57.9) 33 (40.2)
Child class B 15 (39.5) 40 (48.9)
Child class C 1 (2.6) 9 (11.0)
MELD 10.5 ± 2.4 11.8 ± 3.2 0.034
Platelets (×109/L) 83.5 ± 41.2 67.0 ± 49.7 0.003
Albumin (g/dL) 3.4 ± 0.6 3.3 ± 0.6 0.520
Bilirubin (mg/dL) 1.4 ± 0.9 1.6 ± 1.3 0.254
ALT (U/L) 27.4 ± 17.8 42.3 ± 55.8 0.031
AST (U/L) 38.1 ± 27.9 42.5 ± 41.1 0.492
GGT (U/L) 64.2 ± 71.4 43.4 ± 35.4 0.034
AP (U/L) 92.7 ± 56.6 80.5 ± 28.3 0.118
INR 1.3 ± 0.2 1.4 ± 0.3 0.004
Serum creatinine (mg/dL) 0.8 ± 0.2 0.7 ± 0.2 0.602
Serum sodium (mmol/L) 138.9 ± 3.6 138.0 ± 4.3 0.247
Portal vein diameter (mm) 15.6 ± 3.1 16.8 ± 3.3 0.030

BMI, body mass index; HCC, hepatocellular carcinoma; MELD, model of end-stage liver disease score; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyl transpeptidase; AP, alkaline phosphatase; INR, international normalized ratio.